2020

Biomedix receives award from MyTechMag for Best Healthcare Technology Solution Provider
PADnet Xpress is announced, a brand-new device designed to screen for PAD in 2 minutes
The Biomedix Xchange population health management platform is announced
Biomedix announces strategic partnership with BeamMed to market the MiniOmni osteoporosis screening device
Biomedix announces that PADnet Xpress and Biomedix Xchange now support an integrated interface supporting screening for behavioral health conditions like depression and personality disorders
Biomedix announces it has passed electrical safety certification for home use (60601-1-11)
Biomedix announces strategic partnership with Neurometrix to market the DPNCheck peripheral neuropathy screening device

2019

Rich Delperdang is hired as the Chief Growth Officer to focus on value-based care

2018

PADnet and the PADnet.us collaborative care platform achieve HITRUST certification from CSF
Biomedix Awarded “Best Vascular Diagnostic Services Provider” by the Global CEO Excellence Awards issued by CEO Monthly
Biomedix featured in the fall issue of Vein Magazine, in an article titled “4 Critical Reasons to Expand Your Collaborative Care Network with Non-Invasive Vascular Assessments”

2017

2016

The United States Patent & Trademark Office issued U.S. Patent Number 9,245,092, entitled “System and Method for Testing for Cardiovascular Disease”
PADnet 4.0 is announced, featuring a smaller form factor and wireless portability, enhanced security, and faster testing capabilities
PADnet case study featured in Podiatry Management Magazine, titled “Community-Based
Collaborative Care: A Model for Realizing High Quality, Cost-Effective Outcomes”

2015

In conjunction with the SureFit division of Hanger, The Vascular Roundtable Series is launched to provide education on innovative collaborative care models designed to cost effectively improve the health and lives of patients with PAD and CVI

2014

The number of PADnet® tests performed exceeds 800,000
CCD, doing business as Biomedix®, enters into a strategic distribution arrangement with the SureFit division of Hanger, Inc. to promote PADnet to the podiatric physician community
The United States Patent & Trademark Office issued U.S. Patent Number 8,688,472, entitled “System and Method for Testing for Cardiovascular Disease”

2013

Collaborative Care Diagnostics, LLC (CCD) acquires the medical device assets and trade name Biomedix from Biomedix Vascular Solutions, Inc.

2012

The Dual Mode PADnet 2.0 receives FDA 510K clearance. Key enhancements include broadened PAD testing and testing for Chronic Venous Insufficiency (CVI), a disease impacting over 30 million adults in the US
Biomedix introduces VEINnet™ and the next generation of PADnet®
The United States Patent & Trademark Office issued U.S. Patent Number 8,229,762, entitled “System and Method for Testing for Cardiovascular Disease”

2011

The United States Patent & Trademark Office issued U.S. Patent Number 7,983,930, entitled “System and Method for Testing for Cardiovascular Disease”

2010

2009

The number of patients tested using PADnet exceeds 200,000
PADnet Disease Management System (PDMS) is launched, a collaborative care program for hospitals and health systems

2008

2007

PADnet capabilities are expanded to include Post-Exercise testing for enhanced detection of PAD
The total number of PADnet tests performed exceeds 35,000
The United States Patent & Trademark Office issued U.S. Patent Numbers 7,214,192 and 7,172,555, and 7,166,076, entitled “Vascular Testing System”

2006

The number of PADnet tests performed exceeds 20,000. The 20,000th test is performed in a Family Practice medical clinic in North Carolina

2005

PADnet receives The American Podiatric Medical Association (APMA) Seal of Approval. The Seal is designed to inform Podiatric physicians and consumers about quality, safety and effectiveness of medical products
PADnet the 2005 Product Leadership Award from Frost and Sullivan, a leading independent market research firm
The number of PADnet tests performed exceeds 10,000

2004

The PADnet vascular diagnostic device is launched to test for Peripheral Arterial Disease (PAD). PADnet is easy to use, clinically valuable, and provides a fair financial return with medically-appropriate testing. PADnet can be used by medical staff in primary and podiatric care settings and PADnet studies can be interpreted by vascular specialists via secure cloud-based applications.
PADnet receives FDA 510K clearance. This breakthrough technology eliminates the need for Doppler, a technician dependent means of obtaining Ankle-Brachial Indexes (ABI). Instead, PADnet uses recording oscillometric means-measuring oscillations caused by the arterial pressure pulse-to determine segmental blood pressures. Combining ABI with Pulse Volume Recording (PVR) and cloud-based applications, PADnet allows Primary Care Physicians and Podiatric Physicians to communicate remotely with vascular specialists for interpretation of test results and prescription for follow-up care.

Introducing the ETF128 - Video